Modernizing IVF with Marty Gauvin
This episode’s Community Champion Sponsor is Catalyst. To virtually tour Catalyst and claim your space on campus, or host an upcoming event: CLICK HERE
During this episode, we spend time with Marty Gauvin, CEO of Fertilis, a fast-growing startup pioneering precision devices to modernize IVF treatments.
As a serial entrepreneur, Marty is driven to eliminate the heartbreak of infertility impacting millions. While together, Marty shares how Fertilis provides unprecedented environmental control and standardization to improve outcomes. Additionally, Marty unpacks the future of micro-fertility innovations addressing systemic issues limiting accessibility and success rates as well as global population health impacts driving increased prioritization and access.
Join us as Marty advocates for supporting people emotionally and physically on their journey to start a family while also sharing his dedication to helping IVF finally live up to its extraordinary potential through continuous improvements. Let’s go!
- Marty’s startup expertise to transform the IVF experience for patients.
- How Fertilis controls embryos’ environments and reduces variability.
- Marty’s vision is to solve systemic issues limiting IVF’s accessibility and 30% average success rate.
- Why Marty sees global prioritization growing as infertility becomes a population health issue.
- Marty’s commitment to the mission of eliminating the heartbreak of infertility.
About our Guest:
Marty Gauvin is CEO and Co-Founder of Fertilis, where he works to commercialize the team’s pioneering technology and make it accessible to millions of people around the world. Marty is a serial entrepreneur, co-founding several startups including Hostworks, Australia’s largest critical application hosting company, and is currently CEO at Virtual Ark. He served two terms as Chair of The Innovation Investment Committee in the Department of Industry, Innovation and Science in Australia since 2016, which governs the VC sector in Australia. He has been a member of several government and private investment boards that have invested or overseen the investment of billions of dollars into the commercialization of Australian research.
Links Supporting This Episode: